文献速递胰腺与胆道疾病消化内镜

胆胰管镜引导激光切开与消融治疗难治性胰胆管狭窄的长期随访

Long-term follow-up of patients undergoing cholangiopancreatoscopy-guided laser dissection and ablation for refractory pancreatic and biliary strictures (with video).
PubMed 文献 · Gastrointest Endosc · 2025-09-09

本研究为单中心回顾性综述,评估胆胰管镜引导激光切开或消融(CPL)治疗难治性良性胆管和胰管狭窄的疗效与安全性。

要点

  • CPL治疗难治性良性胆胰管狭窄技术成功率100%,完全缓解率61.2%。
  • 中位随访32个月时,45.5%的患者需再次支架干预。
  • 无严重不良事件发生,安全性可接受。

核心结论

  • CPL对良性难治性胆管和胰管狭窄具有高技术成功率和可接受的安全性。

研究设计与样本

  • 单中心回顾性综述,纳入2016年5月至2023年8月因难治性胆管或胰管狭窄接受CPL的30例患者。

主要发现

  • 49处狭窄中完全缓解30处(61.2%),部分缓解17处(34.7%)。
  • 技术成功率为100%。
  • 25例患者(83.3%)在中位6个月(IQR 3-8)后尝试无支架 trial。
  • 22例有随访数据的患者中,45.5%(n=10)需再次支架干预,中位生存时间32个月(95%CI 12-42)。
  • 无严重不良事件发生。

临床怎么用

  • 对于ERCP引导支架置入失败的良性胆胰管狭窄,CPL可作为内镜下治疗选择。

局限性

  • 单中心回顾性设计,样本量较小(30例患者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A subgroup of patients with benign biliary duct (BD) and pancreatic duct (PD) strictures fail to resolve with ERCP-guided stenting. Novel endoscopic approaches are needed. Our study aims to evaluate the efficacy and safety of cholangiopancreatoscopy-guided laser dissection or ablation (CPL) for the treatment of refractory pancreaticobiliary strictures. METHODS: This was a single-center retrospective review of all CPL cases performed for refractory BD or PD strictures. Primary outcome was stricture resolution. Secondary outcomes included technical success, adverse events, and stent-free survival assessed using Kaplan-Meier analysis. RESULTS: Thirty patients underwent CPL from May 2016 to August 2023 and had a median 3 (IQR 1-5) prior ERCPs to treat the stricture(s) of interest. Fifty-three CPLs were performed (median 1 per patient, IQR 1-2) for 49 strictures: 41 PD (83.7%; 17 body, 15 head, 6 neck, and 3 tail) and 8 BD (16.3%; 5 common hepatic duct, 2 common bile duct, and 1 hilum). Complete and partial resolution occurred in 30 (61.2%) and 17 (34.7%) of strictures, respectively. Technical success was 100%. Stent-free trial was attempted in 25 patients (83.3%) after a median of 6 months (IQR 3-8) and median of 4 ERCPs (IQR 2-4) including index CPL and ERCP with stent removal. In 22 patients with follow-up data, reintervention with stenting occurred in 45.5% (n = 10) with a median survival time of 32 months (95% CI, 12-42). No severe adverse events occurred. CONCLUSIONS: CPL has high technical success and an acceptable safety profile for the treatment of benign refractory BD and PD strictures.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Enke T, Rueb N, Pessorrusso F, et al. Long-term follow-up of patients undergoing cholangiopancreatoscopy-guided laser dissection and ablation for refractory pancreatic and biliary strictures (with video). Gastrointest Endosc. 2025. PMID: 40934982. doi:10.1016/j.gie.2025.08.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。